MedPath

MYFEMBREE

MYFEMBREE

Approved
DIN Number

02541742

Drug Class

Human

Market Date

Jan 29, 2024

Company
HC

Sumitomo Pharma Switzerland GmbH

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02541742
AIG Number0365021001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
H01CC54 RELUGOLIX, ESTRADIOL AND NORETHISTERONE
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification68:18.04
Health Canada Classification

ACTIVE INGREDIENTS (3)

ESTRADIOLActive
Strength: 1 MG
Monograph: ESTRADIOL
NORETHINDRONE ACETATEActive
Strength: 0.5 MG
Monograph: NORETHINDRONE ACETATE
RELUGOLIXActive
Strength: 40 MG
Monograph: RELUGOLIX

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.